The U.S. Food and Drug Administration sets a PDUFA target date of June 30, 2026, accelerating review of olezarsen for patients with severe hypertriglyceridemia.
Ionis Pharmaceuticals, Inc. has announced a major regulatory milestone in its efforts to address severe hypertriglyceridemia (sHTG), revealing that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the company’s supplemental New Drug Application (sNDA) for olezarsen. The agency has set a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2026, marking a pivotal step toward potentially expanding treatment options for patients living with this serious and often life-threatening lipid disorder.
The FDA’s acceptance of the sNDA under Priority Review reflects the agency’s recognition of the urgent unmet medical need in severe hypertriglyceridemia. sHTG is characterized by extremely elevated triglyceride levels—typically 500 mg/dL or higher—which significantly increase the risk of acute pancreatitis, a painful and potentially life-threatening inflammatory condition of the pancreas. Recurrent episodes of acute pancreatitis can lead to chronic pancreatic damage, long-term health complications, hospitalizations, and diminished quality of life. Despite available therapies, many patients remain inadequately controlled, leaving them vulnerable to ongoing health risks.
Under the Priority Review designation, the FDA aims to complete its review of the application within six months, compared to the standard 10-month review timeline. This accelerated pathway is reserved for therapies that, if approved, could represent a significant advancement in safety or effectiveness for serious conditions. The agency’s decision underscores the potential clinical importance of olezarsen as a novel therapeutic option for people with sHTG.
Brett P. Monia, Ph.D., Chief Executive Officer of Ionis, emphasized the significance of this milestone, noting that current standard-of-care treatments often provide only limited benefit for individuals with severe hypertriglyceridemia. As a result, many patients continue to face the risk of recurrent and debilitating acute pancreatitis attacks, which may have lasting consequences for overall health. According to Monia, the FDA’s Priority Review designation highlights both the seriousness of the disease and the potential of olezarsen to address a critical gap in treatment. He further stated that this development advances the company’s goal of delivering what could become the first therapy demonstrated to reduce the risk of potentially life-threatening acute pancreatitis events in this patient population.
The sNDA submission and subsequent Priority Review designation are supported by robust data from the Phase 3 CORE and CORE2 clinical studies. These pivotal trials evaluated the efficacy and safety of olezarsen in patients with severe hypertriglyceridemia. Results from the studies showed that olezarsen achieved a highly statistically significant, placebo-adjusted reduction in triglyceride levels of up to 72%. Such reductions are clinically meaningful in a population where elevated triglycerides are directly linked to pancreatitis risk.
Importantly, beyond lowering triglyceride levels, olezarsen demonstrated an 85% reduction in acute pancreatitis events compared to placebo. This finding is particularly notable because, while many lipid-lowering therapies focus on biochemical improvements, few have shown a clear impact on reducing pancreatitis events in patients with severe hypertriglyceridemia. The ability to significantly decrease the occurrence of these attacks represents a potential breakthrough for patients who often endure repeated hospitalizations and substantial physical and emotional burdens.
The trials also reported that nearly 90% of patients treated with olezarsen achieved triglyceride levels below 500 mg/dL. This threshold is widely recognized as a critical marker, as levels below 500 mg/dL are generally considered to reduce the risk of acute pancreatitis. Achieving this level of triglyceride control in the majority of treated patients reinforces the therapeutic potential of olezarsen in managing the disease effectively.
Safety and tolerability data from the CORE and CORE2 studies further supported the therapy’s profile. Olezarsen was generally well tolerated, with a favorable safety profile observed across the trials. This is an essential consideration for patients with sHTG, who may require long-term therapy to maintain triglyceride control and prevent pancreatitis episodes. A therapy that combines strong efficacy with manageable safety characteristics is particularly valuable in chronic conditions requiring sustained treatment.
The clinical findings were published in the prestigious The New England Journal of Medicine and presented at the American Heart Association Scientific Sessions, underscoring the scientific and clinical significance of the data. Publication in a leading peer-reviewed medical journal and presentation at a major cardiovascular conference highlight the broader medical community’s interest in innovative solutions for lipid disorders and their associated complications.
Olezarsen has also previously received Breakthrough Therapy designation from the FDA in November 2025. This designation is granted to investigational therapies that show substantial improvement over existing treatments based on preliminary clinical evidence. Breakthrough Therapy status provides additional FDA guidance and an expedited development and review process, further supporting Ionis’ efforts to bring the therapy to patients as efficiently as possible.
Severe hypertriglyceridemia remains a challenging condition to manage, particularly in patients who do not achieve adequate control with diet, lifestyle modifications, and currently available medications such as fibrates, omega-3 fatty acids, or other lipid-lowering agents. For many individuals, triglyceride levels remain dangerously high despite these interventions, perpetuating the cycle of risk for pancreatitis and other metabolic complications. The development of a targeted therapy capable of delivering substantial triglyceride reductions and meaningful clinical outcomes represents a potentially transformative advance.
If approved, olezarsen could redefine the treatment landscape for sHTG by offering not only significant lipid-lowering effects but also demonstrated reductions in acute pancreatitis risk. Such an outcome would align with evolving regulatory and clinical expectations that therapies address both surrogate biomarkers and tangible clinical endpoints.
With the PDUFA target action date set for June 30, 2026, Ionis now awaits the FDA’s decision. The coming months will involve continued dialogue with the agency as it completes its evaluation of the sNDA. For patients, healthcare providers, and stakeholders, the Priority Review designation signals both urgency and optimism—urgency in addressing a serious and underserved condition, and optimism that a new, effective treatment option may soon become available.
As Ionis advances olezarsen through the regulatory process, this milestone marks a significant step forward in the company’s broader mission to develop innovative therapies for serious diseases. The potential approval of olezarsen could not only improve outcomes for individuals with severe hypertriglyceridemia but also reinforce the promise of next-generation RNA-targeted medicines in addressing complex metabolic disorders.
